Denali Therapeutics (DNLI) Assets Average (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly Assets Average of $1.2 billion for Q1 2026, down 8.87% year-over-year from $1.3 billion in Q1 2025, and up 9.56% quarter-over-quarter from $1.1 billion in Q4 2025.
Denali Therapeutics (DNLI) Assets Average (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Assets Average for 9 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 8.87% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (down 8.87% YoY), while the FY2025 annual figure was $1.3 billion, changed 0.36% from the prior year.
- Assets Average advanced to $1.2 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Assets Average topped out at $1.5 billion in Q2 2024 and bottomed at $1.1 billion in Q4 2025.
- Historically, Assets Average has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2025.
- Annual changes were most pronounced in 2024 — Assets Average advanced 18.3% — and 2025, when it slipped 24.85%.
- Denali Therapeutics' Assets Average stood at $1.3 billion in 2022, then decreased by 11.06% to $1.2 billion in 2023, then rose by 18.3% to $1.4 billion in 2024, then declined by 22.2% to $1.1 billion in 2025, then increased by 9.56% to $1.2 billion in 2026.
- Business Quant data shows DNLI's Assets Average at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 1.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Bn |
| Mar 31, 2026 | 1.21 Bn |
| Dec 31, 2025 | 1.10 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 1.22 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.41 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.54 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Sep 30, 2023 | 1.27 Bn |
| Jun 30, 2023 | 1.36 Bn |
| Mar 31, 2023 | 1.43 Bn |
| Dec 31, 2022 | 1.34 Bn |
| Sep 30, 2022 | 1.26 Bn |
| Jun 30, 2022 | 1.31 Bn |
| Mar 31, 2022 | 1.36 Bn |
| Dec 31, 2021 | 1.43 Bn |
| Sep 30, 2021 | 1.48 Bn |